Search

A number of genetic kidney diseases can now be replicated experimentally, using kidney organoids generated from human pluripotent stem cells. This methodology holds great potential for drug discovery. Under in vitro conditions, however, kidney organoids remain developmentally immature, develop scarce vasculature, and may contain undesired off-target cell types. Those critical deficiencies limit their potential as disease-modeling tools. Orthotopic transplantation under the kidney capsule improves the anatomic maturity and vascularization of kidney organoids, while reducing off-target cell content. The improvements can translate into more accurate representations of disease phenotypes and mechanisms in vivo . Recent studies using kidney organoid xenografts highlighted the unique potential of this novel methodology for elucidating molecular mechanisms driving monogenic kidney disorders and for the development ofnovel pharmacotherapies., (Copyright © 2022 by the American Society of Nephrology.)

During the last decades, the use of nanotechnology in medicine has effectively been translated to the design of drug delivery systems, nanostructured tissues, diagnostic platforms, and novel nanomaterials against several human diseases and infectious pathogens. Nanotechnology-enabled vaccines have been positioned as solutions to mitigate the pandemic outbreak caused by the novel pathogen severe acute respiratory syndrome coronavirus 2. To fast-track the development of vaccines, unprecedented industrial and academic collaborations emerged around the world, resulting in the clinical translation of effective vaccines in less than one year. In this article, we provide an overview of the path to translation from the bench to the clinic of nanotechnology-enabled messenger ribonucleic acid vaccines and examine in detail the types of delivery systems used, their mechanisms of action, obtained results during each phase of their clinical development and their regulatory approval process. We also analyze how nanotechnology is impacting global health and economy during the COVID-19 pandemic and beyond., (© 2021. The Author(s).)

Nanozymes, novel engineered nanomaterial-based artificial enzymes, have been developed to overcome intrinsic drawbacks exist in natural enzymes including high-cost storage, structural instability, and chemical sensitivity. More recently, carbon dots (CDs) have received significant attention due to their biocompatibility, high catalytic activity, and simple surface functionalization, thus emerging as possible alternatives for biomedical and environmental applications. In this review, we analyze methods and precursors used to synthesize CDs with enzyme-mimicking behaviors. In addition, approaches such as doping or constructing hybrid nanozymes are included as possible strategies to enhance the catalytic performance of CDs. Recent studies have reported CDs that mimic different oxidoreductases, exhibiting peroxidase-, catalase-, oxidase/laccase-, and superoxide dismutase-like activities. Therefore, this review presents a detailed discussion of the mechanism, recent advances, and application for each oxidoreductase-like activity reported on nanozymes based on CDs nanomaterials. Finally, current challenges faced in the successful translation of CDs to potential applications are addressed to suggest research directions., (Copyright © 2021 Elsevier B.V. All rights reserved.)

The lack of animal models for some human diseases precludes our understanding of disease mechanisms and our ability to test prospective therapies in vivo. Generation of kidney organoids from Tuberous Sclerosis Complex (TSC) patient-derived-hiPSCs allows us to recapitulate a rare kidney tumor called angiomyolipoma (AML). Organoids derived from TSC2 -/- hiPSCs but not from isogenic TSC2 +/- or TSC2 +/+ hiPSCs share a common transcriptional signature and a myomelanocytic cell phenotype with kidney AMLs, and develop epithelial cysts, replicating two major TSC-associated kidney lesions driven by genetic mechanisms that cannot be consistently recapitulated with transgenic mice. Transplantation of multiple TSC2 -/- renal organoids into the kidneys of immunodeficient rats allows us to model AML in vivo for the study of tumor mechanisms, and to test the efficacy of rapamycin-loaded nanoparticles as an approach to rapidly ablate AMLs. Collectively, our experimental approaches represent an innovative and scalable tissue-bioengineering strategy for modeling rare kidney disease in vivo., (© 2021. The Author(s).)